| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1021951445 |
| P356 | DOI | 10.1007/S12013-015-0526-7 |
| P698 | PubMed publication ID | 25616442 |
| P2093 | author name string | Jie Li | |
| Jian Kong | |||
| Ou Yang | |||
| P2860 | cites work | Caveolae: mining little caves for new cancer targets | Q35190153 |
| Nitric oxide and cardiac function: ten years after, and continuing | Q35213031 | ||
| Endothelial function and clinical outcome | Q35584760 | ||
| Nitric oxide's role in the heart: control of beating or breathing? | Q35813373 | ||
| Endothelium-targeted gene and cell-based therapies for cardiovascular disease. | Q35861913 | ||
| Functional and morphological studies of protein transcytosis in continuous endothelia | Q35913804 | ||
| Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure | Q36100943 | ||
| Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors | Q36253833 | ||
| Advanced drug delivery systems that target the vascular endothelium | Q36432209 | ||
| Endothelial mechanotransduction, nitric oxide and vascular inflammation. | Q36440491 | ||
| Potential of gene therapy as a treatment for heart failure | Q36497159 | ||
| Vascular endothelium in atherosclerosis. | Q37271748 | ||
| Endothelial dysfunction and vascular disease | Q37394140 | ||
| Endothelial dysfunction: methods of assessment & implications for cardiovascular diseases | Q37790732 | ||
| Endothelial dysfunction, arterial stiffness, and heart failure | Q38045605 | ||
| Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling | Q40016210 | ||
| Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. | Q40888989 | ||
| Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. | Q41224359 | ||
| Local L-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm | Q41765313 | ||
| Effect of vasoactive peptides on prostacyclin synthesis in man. | Q41776050 | ||
| Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation. | Q42160647 | ||
| Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure | Q42522364 | ||
| Blunted peripheral vasodilatory response is a hallmark of progressive deterioration in mild to moderate congestive heart failure | Q43551214 | ||
| Vitamin C inhibits endothelial cell apoptosis in congestive heart failure | Q43783257 | ||
| Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis | Q44706286 | ||
| Endothelial dysfunction | Q45000505 | ||
| The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury. | Q45957622 | ||
| Therapeutic strategies for endothelial dysfunction | Q46470925 | ||
| Neutrophil superoxide anion--generating capacity, endothelial function and oxidative stress in chronic heart failure: effects of short- and long-term vitamin C therapy | Q49050596 | ||
| Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors | Q54267978 | ||
| Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells | Q58816342 | ||
| Nanocarriers for vascular delivery of antioxidants | Q27027067 | ||
| Therapeutic approach in the improvement of endothelial dysfunction: the current state of the art | Q27027533 | ||
| The vascular endothelium and human diseases | Q28302238 | ||
| The reaction of no with superoxide | Q28611742 | ||
| The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine | Q29547539 | ||
| Redox state, oxidative stress and endothelial dysfunction in heart failure: the puzzle of nitrate-thiol interaction. | Q33344645 | ||
| Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers | Q33606794 | ||
| Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue | Q33637063 | ||
| Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4. | Q34953389 | ||
| AVE3085, an enhancer of endothelial nitric oxide synthase, restores endothelial function and reduces blood pressure in spontaneously hypertensive rats | Q35089883 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| endothelium | Q111140 | ||
| P304 | page(s) | 751-756 | |
| P577 | publication date | 2015-01-24 | |
| P1433 | published in | Cell Biochemistry and Biophysics | Q15755135 |
| P1476 | title | The Endothelium as a Target for the Treatment of Heart Failure | |
| P478 | volume | 72 |
| Q37261607 | Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure. |
| Q38999245 | Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications |
| Q35537186 | Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders |
Search more.